DDW has published the latest addition to its Guide Series, ‘Find out about the global breakthroughs, opportunities and developments in cancer research.’ It is sponsored by IRBM. In this free, exclusive guide, you will learn more about: Where the global breakthroughs, opportunities and developments are in cancer research Why cancer-associated… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More
News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer. As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world. The… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments in the treatment of solid tumours… Read More
News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More
Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC). … Read More
Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As well as providing extensive coverage of the … Read More
News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer. As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a… Read More
CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer. The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial… Read More
DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More
Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients. The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More
Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was… Read More
Pierre Fabre will commercialise and distribute the first approved allogeneic T cell immunotherapy in Europe following the transfer of the European Commission marketing authorisation of Ebvallo (tabelecleucel) from Atara Biotherapeutics. Ebvallo is the only approved therapy for the treatment of relapsed or refractory Epstein‑Barr virus positive post‑transplant… Read More
Listen to this article on the DDW Podcast: Why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer. A Phase III clinical trial has produced promising results for a cancer vaccine targeting patients with a new or recurrent… Read More
Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)… Read More
